Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Arch Gynecol Obstet ; 310(1): 45-54, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38806942

RESUMEN

PURPOSE: The prevalence of benzodiazepines and related drugs (BZRDs) use during pregnancy increased sharply in recent years. Thus, there are concerns regarding the pregnancy outcomes following exposure to BZRDs. METHODS: Two electronic databases were thoroughly searched to identify related clinical studies published from inception until June 2023. English-language cohort studies with high-quality comparing antenatal BZRDs exposure to an unexposed group on any delivery outcome were included. RESULTS: Ten cohort studies that estimated adverse neonatal outcomes associated with exposure to BZRDs during pregnancy were included. Exposure to BZRDs during pregnancy was associated with an increased risk of congenital malformation [odds ratio (OR) 1.09, 95% confidence interval (CI) 1.05-1.13, p < 0.001], heart malformation (OR 1.13, 95% CI 1.04-1.22, p = 0.003), preterm birth (OR 1.45, 95% CI 1.23-1.7, p < 0.001), SGA (OR 1.18, 95% CI 1.08-1.29, P < 0.001), LBW (OR 1.42, 95% CI 1.25-1.6, p = 0.001) or low Apgar score (OR 1.42, 95% CI 1.08-1.87, p = 0.011),compared with no exposure. Further analyses limited to the first trimester exposure yielded consistent results. CONCLUSIONS: Exposure to BZRDs during pregnancy may be associated with several adverse neonatal outcomes. However, we could not rule out the potential indication confounding factor, further studies with high-quality that control for important confounders are still needed to verify our findings.


Asunto(s)
Benzodiazepinas , Resultado del Embarazo , Humanos , Embarazo , Femenino , Benzodiazepinas/efectos adversos , Resultado del Embarazo/epidemiología , Recién Nacido , Nacimiento Prematuro/epidemiología , Anomalías Inducidas por Medicamentos/epidemiología , Anomalías Inducidas por Medicamentos/etiología , Estudios de Cohortes , Complicaciones del Embarazo
2.
Fitoterapia ; 176: 106000, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38729248

RESUMEN

Five new characteristic cembrane-type diterpenoids (olibacartiols A-E, 1-5) were acquired from the gum resin of Boswellia carterii. The structures of these diterpenoids were characterized by detailed spectroscopic analysis, and compounds 1-3 were unambiguously confirmed by single-crystal X-ray diffraction experiments. The anti-inflammatory activities of the isolated compounds were evaluated using LPS-induced BV2 cell model and compounds 2-5 showed moderate NO inhibitory effects with IC50 values of 8.84 ± 1.02, 9.82 ± 1.95, 9.75 ± 2.24, and 7.39 ± 1.24 µM, respectively.


Asunto(s)
Antiinflamatorios , Boswellia , Diterpenos , Óxido Nítrico , Fitoquímicos , Resinas de Plantas , Diterpenos/farmacología , Diterpenos/aislamiento & purificación , Diterpenos/química , Boswellia/química , Óxido Nítrico/metabolismo , Estructura Molecular , Animales , Antiinflamatorios/farmacología , Antiinflamatorios/aislamiento & purificación , Antiinflamatorios/química , Resinas de Plantas/química , Ratones , Fitoquímicos/farmacología , Fitoquímicos/aislamiento & purificación , Línea Celular , China , Gomas de Plantas/química , Gomas de Plantas/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...